Skip to main content
. Author manuscript; available in PMC: 2021 Jun 22.
Published in final edited form as: Cerebellum. 2021 Jan 4;20(3):420–429. doi: 10.1007/s12311-020-01226-3

Figure 2. Post-symptomatic BDNF delivery ameliorates motor deficits.

Figure 2.

A. Rotarod performance of mice at 16 weeks, two weeks after the start of treatment (WT aCSF (N=15), WT BDNF (N=10), ATXN1[82Q] aCSF (N=12), and ATXN1[82Q] BDNF (N=16). B. Rotorod performance of mice at 19 weeks, one week after the cessation of treatment (ATXN1[82Q] aCSF, N=11, ATXN1[82Q] BDNF, N=15). Each data point represent individual mouse, bars show the average with error bars = SEM. * P<0.05, one-way ANOVA with post hoc Sidak’s test.